Biomater. Sci., 2024, 12,1822-1840
DOI: 10.1039/D3BM01931D, Paper
DOI: 10.1039/D3BM01931D, Paper
Open Access
This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.Robert J. Cavanagh, Patrícia F. Monteiro, Cara Moloney, Alessandra Travanut, Fatemeh Mehradnia, Vincenzo Taresco, Ruman Rahman, Stewart G. Martin, Anna M. Grabowska, Marianne B. Ashford, Cameron Alexander
Combinations of the topoisomerase II inhibitor doxorubicin and the poly (ADP-ribose) polymerase inhibitor olaparib offer potential drug–drug synergy for treatment of triple negative breast cancers (TNBC) both in free drug form and when delivered by oxidation-responsive nanoparticles.
The content of this RSS Feed (c) The Royal Society of Chemistry
Combinations of the topoisomerase II inhibitor doxorubicin and the poly (ADP-ribose) polymerase inhibitor olaparib offer potential drug–drug synergy for treatment of triple negative breast cancers (TNBC) both in free drug form and when delivered by oxidation-responsive nanoparticles.
The content of this RSS Feed (c) The Royal Society of Chemistry